CoChat

Ciclopirox Olamine Treatment Affects the Expression Pattern of Candida albicans Genes Encoding Virulence Factors, Iron Metabolism Proteins, and Drug Resistance Factors

Open access
Niewerth, Markus, Kunze, Donika, Seibold, Michael, Schaller, Martin, Korting, Hans Christian, Hube, Bernhard · 2003 · Antimicrobial Agents and Chemotherapy
Cited by 144

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

The hydroxypyridone ciclopirox olamine belongs to the antimycotic drugs used for the treatment of superficial mycoses. In contrast to the azoles and other antimycotic drugs, its specific mode of action is only poorly understood. To investigate the mode of action of ciclopirox olamine on fungal viability, pathogenicity, and drug resistance, we examined the expression patterns of 47 Candida albicans genes in cells grown in the presence of a subinhibitory concentration (0.6 μg/ml) of ciclopirox olamine by reverse transcription-PCR. In addition, we used suppression-subtractive hybridization to further identify genes that are up-regulated in the presence of ciclopirox olamine. The expression of essential genes such as ACT1 was not significantly modified in cells exposed to ciclopirox olamine. Most putative and known virulence genes such as genes encoding secreted proteinases or lipases had no or only moderately reduced expression levels. In contrast, exposure of cells to ciclopirox olamine led to a distinct up- or down-regulation of genes encoding iron permeases or transporters (FTR1,FTR2,FTH1), a copper permease (CCC2), an iron reductase (CFL1), and a siderophore transporter (SIT1); these effects resembled those found under iron-limited conditions. Addition of FeCl 3 to ciclopirox olamine-treated cells reversed the effect of the drug. Addition of the iron chelator bipyridine to the growth medium induced similar patterns of expression of distinct iron-regulated genes (FTR1,FTR2). While serum-induced yeast-to-hyphal phase transition of C. albicans was not affected in ciclopirox olamine-treated cells in the presence of subinhibitory conditions, a dramatic increase in sensitivity to oxidative stress was noted, which may indicate the reduced activities of iron-containing gene products responsible for detoxification. Although the Candida drug resistance genes CDR1 and CDR2 were up-regulated, no change in resistance or increased tolerance could be observed even after an incubation period of 6 months. This was in contrast to control experiments with fluconazole, in which the MICs for cells incubated with this drug had noticeably increased after 2 months. These data support the view that the antifungal activity of ciclopirox olamine may at least be partially caused by iron limitation. Furthermore, neither the expression of certain multiple-drug resistance genes nor other resistance mechanisms caused C. albicans resistance to this drug even after long-term exposure.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.47.6.1805-1817.2003

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 48

  1. Abrams, B. B., H. Hänel, and T. Hoehler. 1992. Ciclopirox olamine: a hydroxypyridone antifungal agent. Clin. Dermatol.9:471-477.
  2. 10.1128/jb.179.23.7210-7218.1997 · DOI · Paper page
  3. 10.1128/AAC.44.5.1255-1265.2000 · DOI · Paper page
  4. 10.1099/00221287-144-1-55 · DOI · Paper page
  5. 10.1128/AAC.38.4.648 · DOI · Paper page
  6. Braga, P. C., S. Maci, M. DalSasso, and M. Bohn. 1996. Experimental evidences for a role of subinhibitory concentrations of rilopirox, nystatin and fluconazole on adherence of Candida spp. to vaginal epithelial cells. Chemotherapy (Basel)42:259-265. · doi:10.1159/000239453
  7. Braga, P. C., G. Piatti, E. Conti, and F. Vignali. 1992. Effects of subinhibitory concentrations of ciclopirox on the adherence of Candida albicans to human buccal and vaginal epithelial cells. Drug Res.42:1368-1371.
  8. 10.1126/science.277.5322.105 · DOI · Paper page
  9. 10.1093/genetics/155.1.57 · DOI · Paper page
  10. 10.1099/00221287-146-11-2743 · DOI · Paper page
  11. Diasio, R. B., J. E. Bennett, and C. E. Myers. 1978. Mode of action of 5-fluorocytosine. Biochem. Pharmacol.27:703. · DOI
  12. 10.1073/pnas.93.12.6025 · DOI · Paper page
  13. Dittmar, W., W. Grau, W. Raether, E. Schrinner, and W. H. Wagner. 1981. Microbiological laboratory studies with ciclopiroxolamine. Drug Res.31:1317-1322.
  14. Dittmar, W., and G. Lohaus. 1973. HOE 296, a new antimycotic compound with a broad antimicrobial spectrum. Drug Res.23:670-674.
  15. 10.1099/00221287-145-9-2415 · DOI · Paper page
  16. 10.1128/IAI.70.7.3689-3700.2002 · DOI · Paper page
  17. 10.1007/BF00259685 · DOI · Paper page
  18. 10.1016/S0378-1119(98)00412-0 · DOI
  19. 10.1099/00221287-143-2-331 · DOI
  20. Gasparini, G., D. Contini, A. Torti, C. Guidarelli, A. Lasagni, and R. Caputo. 1986. The effect of ciclopiroxolamine investigated by means of the freeze-fracture technique. Mykosen29:539-544. · doi:10.1111/j.1439-0507.1986.tb03956.x
  21. Gupta, A. K. 2001. Ciclopirox: an overview. Int. J. Dermatol.40:305-310. · DOI
  22. 10.1016/S0190-9622(94)70112-1 · DOI
  23. 10.1111/j.1574-6968.1998.tb13223.x · doi:10.1111/j.1574-6968.1998.tb13223.x · Paper page
  24. 10.1099/00221287-147-4-879 · DOI · Paper page
  25. 10.1099/00221287-147-8-1997 · DOI · Paper page
  26. 10.1111/j.1365-2958.1994.tb01269.x · DOI · Paper page
  27. 10.1128/IAI.69.6.3939-3946.2001 · DOI
  28. Iwata, K., and H. Yamaguchi. 1981. Studies on the mechanism of antifungal action of ciclopiroxolamine. Drug Res.31:1323-1327.
  29. 10.1128/jb.179.7.2331-2338.1997 · DOI · Paper page
  30. Korting, H. C., and M. Grundmann-Kollmann. 1997. The hydroxypyridones: a class of antimycotics of its own. Mycoses40:243-247. · DOI · Paper page
  31. Kruse, R., W. Hengstenberg, H. Hänel, and W. Raether. 1991. Studies for the elucidation of the mode of action of the antimycotic hydroxypyridone compound, rilopirox. Pharmacology43:247-255. · doi:10.1159/000138852
  32. 10.1016/S0378-1119(97)00069-3 · DOI
  33. Lohaus, G., and W. Dittmar. 1981. The chemistry of antimicrobially active 1-hydroxy-2-pyridones. Drug Res.31:1311-1316.
  34. Losberger, C., and J. F. Ernst. 1989. Sequence of the Candida albicans gene encoding actin. Nucleic Acids Res.17:9488. · DOI · Paper page
  35. 10.1093/jac/47.5.527 · DOI · Paper page
  36. Maneu, V., A. M. Cervera, J. P. Martinez, and D. Gozalbo. 1996. Molecular cloning and characterization of a Candida albicans gene (EFB1) coding for the elongation factor EF-1β. FEMS Microbiol. Lett.145:157-162.
  37. Mercer, E. I. 1991. Morpholine antifungals and their mode of action. Biochem. Soc. London Trans.19:788-793. · doi:10.1042/bst0190788
  38. Reitze, H. K., D. R. Dannhorn, H. Hänel, and K. A. Seitz. 1993. Ultrastructural investigations of Candida albicans after in vitro treatment with the new fungicidal agent rilopirox. Mycoses36:385-395. · doi:10.1111/j.1439-0507.1993.tb00727.x
  39. Sakurai, K., T. Sakaguchi, H. Yamaguchi, and K. Iwata. 1978. Mode of action of 6-cyclohexyl-4-methyl-2(1H)-pyridone ethanolamine salt (HOE 296). Chemotherapy (Tokyo)24:68-76. · DOI
  40. Sakurai, K., T. Sakaguchi, H. Yamaguchi, and K. Iwata. 1978. Studies on uptake of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone ethanolamine salt (HOE 296) by Candida albicans. Chemotherapy (Tokyo)24:146-153. · doi:10.1159/000237774
  41. Sambrook J. and D. W. Russell. 2001. Molecular cloning: a laboratory manual 3rd ed. Cold Spring Harbor Laboratory Press Cold Spring Harbor N.Y.
  42. 10.1099/00221287-143-2-405 · DOI · Paper page
  43. 10.1016/S1473-3099(02)00181-0 · DOI · Paper page
  44. 10.1016/0378-1119(93)90668-S · DOI
  45. Sugiyama, Y., S. Nakashima, F. Mirbod, H. Kanoh, Y. Kitajima, M. A. Ghannoum, and Y. Nozawa. 1999. Molecular cloning of a second phospholipase B gene, CaPLB2 from Candida albicans. Med. Mycol.37:61-67.
  46. 10.1074/jbc.274.53.38061 · DOI · Paper page
  47. 10.1128/CMR.11.2.382 · DOI · Paper page
  48. 10.1128/IAI.66.5.1953-1961.1998 · DOI · Paper page

Cited by

See all 144

Metadata

Authors
Niewerth, M., Kunze, D., Seibold, M., Schaller, M., Korting, H. C., & Hube, B.
Venue
Antimicrobial Agents and Chemotherapy
Published
2003-06
Volume
47
Issue
6
Pages
1805-1817
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W2095902301
Cited by
144
References
11
FWCI
2.04
Type
journal article
Language
en
Open access
green
Licence
journals.asm.org/non-commercial-tdm-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ciclopirox Olamine Treatment Affects the Expression Pattern of Candida albicans Genes Encoding Virulence Factors, Iron Metabolism Proteins, and Drug Resistance Factors. https://app.cochat.ai/papers/10.1128/aac.47.6.1805-1817.2003
The paper
Niewerth, M., Kunze, D., Seibold, M., Schaller, M., Korting, H. C., & Hube, B. (2003). Ciclopirox Olamine Treatment Affects the Expression Pattern of Candida albicans Genes Encoding Virulence Factors, Iron Metabolism Proteins, and Drug Resistance Factors. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.47.6.1805-1817.2003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.